MAGNESIUM IN THE TREATMENT AND PREVENTION OF MIGRAINE
Abstract
Magnesium — intracellular cation — is important in many pathological processes including the pathogenesis of migraine. Magnesium deficiency in patients with migraine may be developed as a result of genetic inability to absorb magnesium and its excessive loss with stress because of low nutritional intake and a number of other reasons. Migraine magnesium deficiency contributes in changing the activity of NMDA-receptors, distribution of cortical depression hyperaggregation platelets, affects the function of serotonin receptors and metabolism of many neurotransmitters. Intravenous magnesium-containing drugs show high efficacy in the treatment and prevention of migraine.
About the Authors
E. S. Akarachkova
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
E.S. Akarachkova, PhD, senior researcher of the Laboratory of pathology of autonomic nervous system of the Research Centre
A. R. Artemenko
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
A.R. Artemenko, MD, senior researcher of the Laboratory of pathology of autonomic nervous system of the Research Centre
References
1. Goksel B.K. et al. Is low blood magnesium level associated with hemodialysis headache? // Headache. — 2006. — Vol. 46(1). — P. 40–45.
2. Lodi R. et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache // Brain Res. Bull. — 2001. — Vol. 54(4). — P. 437–441.
3. Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium // J. Neural. Transm. — 2012. — Vol. 119(5). — P. 575–579.
4. Talebi M. et al. Relation between serum magnesium level and migraine attacks // Neurosciences. — 2011. — Vol. 16(4). — P. 320–323.
5. Trauninger A., Pfund Z., Koszegi T., Czopf J. Oral magnesium load test in patients with migraine // Headache. — 2002. — Vol. 42(2). — P. 114–119.
6. Gallai V. et al. Serum and salivary magnesium levels in migraine. Results in a group of juvenile patients // Headache. — 1992. — Vol. 32(3). — P. 132–135.
7. Samaie A., Asghari N., Ghorbani R., Arda J. Blood Magnesium levels in migraineurs within and between the headache attacks: a case control study // Pan. Afr. Med. J. — 2012. — Vol. 11. — P. 46.
8. Dhillon K.S., Singh J., Lyall J.S. A new horizon into the pathobiology, etiology and treatment of migraine // Med. Hypotheses. — 2011. — Vol. 77(1). — P. 147–151.
9. Rosanoff A., Weaver C.M., Rude R.K. Suboptimal magnesium status in the United States: are the health consequences underestimated? // Nutr. Rev. — 2012. — Vol. 70(3). — P. 153–164.
10. Altura B.T., Altura B.M. Role of excitatory amino acids in regulation of rat pial microvasculature // Am. J. Physiol. — 1994. — Vol. 266. — P. 158–163.
11. Громова О.А. Магний и пиридоксин: основы знаний. — М., 2006. — 223 с.
12. Chen Y. Advances in the pathophysiology of tension-type headache: from stress to central sensitization // Curr. Pain Headache Rep. — 2009. — Vol. 13(6). — P. 484–494.
13. Громова О.А., Торшин И.Ю., Гришина Т.Р. Мировой опыт применения цитрата магния в медицине // Трудный пациент. — 2010. — № 8. — Т. 8. — С. 35–38.
14. Акарачкова Е.С., Вершинина С.В. Дефицит магния у неврологических пациентов: миф или реальность? // РМЖ. — 2011. — № 15. — Т. 19. — С. 987–991.
15. Hazardous chemicals in human and environmental health. — WHO, 2002. — P. 312.
16. Городецкий В.В., Талибов О.Б. «Препараты магния в медицинской практике». (Малая энциклопедия магния). — М., 2003. — 44 с.
17. Акарачкова Е.С. Хронический стресс и нарушение профессиональной адаптации // Журнал неврологии и психиатрии им. С.С. Корсакова. — 2011. — Вып. 111(5). — С. 56–59.
18. Corbo J., Esses D., Bijur P.E., Iannaccone R., Gallagher E.J. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache // Ann. Emerg. Med. — 2001. — Vol. 38(6). — P. 621–627.
19. Bigal M.E., Bordini C.A., Tepper S.J., Speciali J.G. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study // Cephalalgia. — 2002. — Vol. 22(5). — P. 345–353.
20. Cete Y., Dora B., Ertan C., Ozdemir C., Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department // Cephalalgia. — 2005. — Vol. 25(3). — P. 199–204.
21. Guerrera M.P., Volpe S.L., Mao J.J. Therapeutic uses of magnesium // Am. Fam. Physician. — 2009. — V ol. 80(2). — P. 157–162.
22. Robertson C.E., Black D.F., Swanson J.W. Management of migraine headache in the emergency department // Semin. Neurol. — 2010. — Vol. 30(2). — P. 201–211.
23. Pringsheim T. et al. Canadian headache society prophylactic guidelines development group. Canadian headache society guideline for migraine prophylaxis // Can. J. Neurol. Sc. — 2012. — Vol. 39. — P. 1–59.
24. Silberstein S.D., Goadsby P.J. Migraine: preventive treatment. — Cephalalgia. — 2002. — Vol. 22. — P. 491–512.
25. Snow V., Weiss K., Wall E.M., Mottur-Pilson C. American academy of family physicians. American college of physicians. American society of internal medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache // Ann. Intern. Med. — 2002. — Vol. 137. — P. 840–849.
26. Modi S., Lowder D.M. Medications for migraine prophylaxis // Am. Fam. Physician. — 2006. — Vol. 73(1). — P. 72–78.
27. Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans // Am. J. Ther. — 2001. — Vol. 8(5). — P. 345–357.
28. Sriboonlue P. et al. Changes in erythrocyte contents of potassium, sodium and magnesium and Na-, K-pump activity after the administration of potassium and magnesium salts // J. Med. Assoc. Thai. — 2004. — Vol. 87(12). — P. 1506–1512.
29. Coudray C. et al. Study of magnesium bioavailability from ten organicand inorganic Mg salts in Mg-depleted rats using a stable isotope approach // Magnes Res. — 2005. — Vol. 18(4). — P. 215–223.
30. Lindberg J.S., Zobitz M.M., Poindexter J.R., Pak C.Y. Magnesium bioavailability from magnesium citrate and magnesium oxide // J. Am. Coll. Nutr. — 1990. — Vol. 9(1). — P. 48–55.
31. Torshin I.Yu, Gromova OA. Magnesium and pyridoxine: fundamental studies and clinical practice // Nova Science. — 2009. — Vol. 250.
32. Walker A.F., Marakis G., Christie S., Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study // Magnes Res. — 2003. — Vol. 16(3). — P. 183–191.
33. Köseoglu E., Talaslioglu A., Gönül A.S., Kula M. The effects of magnesium prophylaxis in migraine without aura // Magnes Res. — 2008. — Vol. 21(2). — P. 101–108.
34. Li W., Zheng T., Altura B.M., Altura B.T. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence // Brain Res Bull. — 2001. — Vol. 54(1). — P. 83–89.
35. Mauskop A., Altura B.T., Altura B.M. Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine // Headache. — 2002. — Vol. 42(4). — P. 242–248.
36. Evers S. Alternatives to beta blockers in preventive migraine treatment // Nervenarzt. — 2008. — Vol. 79(10). — P. 1135–1143.
37. Lakhan S.E., Vieira K.F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review // Nutr. J. — 2010. — Vol. 9. — P. 42.
38. Abumaria N. et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala // J. Neurosc. — 2011. — Vol. 31(42). — P. 871–881.
39. Musante V., Summa M., Cunha R.A., Raiteri M., Pittaluga A. Pre-synaptic glycine GlyT1 transporter — NMDA receptor interaction: relevance to NMDA autoreceptor activation i n the presence of Mg2+ions // J. Neurochem. — 2011. — Vol. 117(3). — P. 516–527.
40. Sartori S.B., Whittle N., Hetzenauer A., Singewald N. Magnesium defi ciency induces anxiety and HPA axis dysregulation: modulation by therapeutic drug treatment // Neuropharmacology. — 2012. — Vol. 62(1). — P. 304–312.
Review
Views:
762
Email this article 